Isolated Lactobacillus strains are useful in preventing or delaying the development of Type 1 Diabetes (T1D). A probiotic composition comprising the Lactobacillus strains and use of the composition in T1D prevention are provided.

Provided is a composition containing Lactobacillus reuteri ELF corresponding to a novel lactic acid bacteria strain and 5-aminolevulinic acid. The composition may be significantly effective to prevent and treat degenerative brain disease and have excellent anti-obesity and anti-diabetes effects, such that the present invention may provide various pharmaceutical composition, health foods, and the like, using the same.

Provided is a composition containing Lactobacillus reuteri ELF corresponding to a novel lactic acid bacteria strain and 5-aminolevulinic acid. The composition may be significantly effective to prevent and treat degenerative brain disease and have excellent anti-obesity and anti-diabetes effects, such that the present invention may provide various pharmaceutical composition, health foods, and the like, using the same.

The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strain's capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs.

The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strain's capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs.

The present invention is a yogurt product that may be consumed by dogs and other mammalian pets. The yogurt product is in an unflavored form comprising as essential constituents: (A) 0% to 88% by weight water; (B) 0.2% to 25% by weight of a no-fat protein component selected from the group consisting of skim milk and cultured skim milk; (C1) 0.001% to 6% by weight sugar component comprising: (C1) 0.001% to 6% polydextrose and (C2) 0.001% to 6% Glycoses and Galactoses; (D) 2% to 8% by weight milk derived solids; (E) 0.2% to 2.5% by weight stabilizers and emulsifiers; and (F) at least one probiotic microorganism. The yogurt product may be refrigerated and served as a mousse, frozen dessert, or as a fermented yogurt drink similar to Ayran or Kefir. A method for producing the yogurt product is also disclosed herein.

The disclosure discloses application of breast milk-derived Lactobacillus reuteri in regulating the maternal and infant immune function, belonging to the fields of microbiological technology and food science. The disclosure provides the effects of Lactobacillus reuteri Fn041 in enhancing the immunity of pregnant or lactating women and infants, i.e., enhancing the mucosal barrier, promoting the production of intestinal antibacterial peptides and IgA, promoting the development of the immune system of infants, preventing pathogen infection and reducing the incidence of allergic diseases.

The disclosure discloses application of breast milk-derived Lactobacillus reuteri in regulating the maternal and infant immune function, belonging to the fields of microbiological technology and food science. The disclosure provides the effects of Lactobacillus reuteri Fn041 in enhancing the immunity of pregnant or lactating women and infants, i.e., enhancing the mucosal barrier, promoting the production of intestinal antibacterial peptides and IgA, promoting the development of the immune system of infants, preventing pathogen infection and reducing the incidence of allergic diseases.

A sweetener composition comprising xylose, a sugar alcohol and brown seaweed extract in solid form, preferably powdered or crystalline form. The sugar alcohol is preferably an erythritol and the brown seaweed extract is preferably obtained from Laminaria japonica. The sweetener composition can further comprise one or a combination of additional vitamins, minerals, probiotic cultures, and other plant-based extracts.

The present invention relates to a prebiotic composition comprising a microbially produced oligosaccharide, wherein the oligosaccharide is characterized by being selective for a pre-determined probiotic bacterial strain and also capable of being produced by the pre-determined probiotic bacteria by reverse enzyme action. The present invention also relates to methods of screening a composition suitable for use as a prebiotic and methods for screening of prebiotics for incorporation into synbiotic formulations.